David Goldscher, MD, FACC, is an Associate Cardiologist at MedStar Union Memorial Hospital and MedStar Franklin Square Medical Center and has a clinical practice at MedStar Health Chesapeake CardioVascular Associates. In addition to his clinical responsibilities, he is an Instructor in Medicine at the University of Maryland in Baltimore.
Dr. Goldscher has been a principal or co-investigator on more than 50 clinical trials, including Treating to New Targets (TNT), Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS), and Aggressive Reduction of Inflammation Stops Events (ARISE).
He is a fellow of the American College of Cardiology, a member of the American College of Physicians, and a Diplomat of the American Board of Internal Medicine. He is certified in Internal Medicine and Cardiovascular Disease.
His medical degree is from the University of Maryland School of Medicine in Baltimore, where he also completed a residency as a Junior and Senior Assistant Resident in Medicine and a fellowship in Cardiovascular Medicine.
Dr. Goldscher's research interests include
- Preventive cardiology
- Drug trials
- Cardiovascular diseases
- Congestive heart failure
Dabigatran versus warfarin in patients with atrial fibrillation
In an article published in the New England Journal of Medicine (2009;361:1139-51), Dr. Goldscher and other investigators examined the effects of dabigatran versus warfarin. The authors found that in patients with atrial fibrillation, dabigatran (110 mg) was associated with rates of stroke and systemic embolism similar to those associated with warfarin, but lower rates of hemorrhage.
PEGASUS-Thrombolysis in Myocardial Infarction (TIMI) 54
Dr. Goldscher is a principal investigator on the PEGASUS-TIMI 54 trial, sponsored by AstraZeneca. This randomized, double-blind, placebo controlled, parallel group, multinational trial is designed to assess the efficacy of ticagrelor compared with placebo in preventing death from heart disease, heart attack, or stroke in patients with a history of myocardial infarction and taking acetyl salicylic acid therapy.
- Research Areas